Astrazeneca PLC (NYSE:AZN) shares saw unusually-strong trading volume on Monday . Approximately 6,102,077 shares were traded during trading, a decline of 12% from the previous session’s volume of 6,946,808 shares.The stock last traded at $31.20 and had previously closed at $31.13.

A number of equities analysts have commented on AZN shares. Bank of America Corp. reissued a “buy” rating and set a $36.65 target price on shares of Astrazeneca PLC in a report on Monday, July 18th. Citigroup Inc. reissued a “buy” rating on shares of Astrazeneca PLC in a report on Saturday, June 25th. Argus started coverage on Astrazeneca PLC in a report on Tuesday, July 12th. They set a “hold” rating for the company. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Astrazeneca PLC in a report on Thursday, April 21st. Finally, Goldman Sachs Group Inc. cut Astrazeneca PLC from a “neutral” rating to a “sell” rating in a report on Monday, April 11th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. Astrazeneca PLC has an average rating of “Buy” and an average price target of $562.78.

The firm has a market cap of $78.81 billion and a P/E ratio of 27.09. The firm’s 50 day moving average price is $29.42 and its 200-day moving average price is $29.52.

Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Friday, April 29th. The company reported $0.51 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by $0.09. The firm had revenue of $6.12 billion for the quarter, compared to the consensus estimate of $5.96 billion. During the same period last year, the firm earned $1.08 earnings per share. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. On average, equities analysts predict that Astrazeneca PLC will post $2.36 EPS for the current year.

A number of institutional investors have recently made changes to their positions in AZN. Genesee Valley Trust Co. increased its position in shares of Astrazeneca PLC by 5.4% in the fourth quarter. Genesee Valley Trust Co. now owns 31,627 shares of the company’s stock valued at $1,074,000 after buying an additional 1,617 shares in the last quarter. Bailard Inc. purchased a new position in shares of Astrazeneca PLC during the fourth quarter valued at about $3,402,000. Quantitative Investment Management LLC purchased a new position in shares of Astrazeneca PLC during the fourth quarter valued at about $1,782,000. Sei Investments Co. increased its position in shares of Astrazeneca PLC by 279.5% in the fourth quarter. Sei Investments Co. now owns 108,458 shares of the company’s stock valued at $3,683,000 after buying an additional 79,882 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of Astrazeneca PLC by 8.2% in the fourth quarter. US Bancorp DE now owns 126,767 shares of the company’s stock valued at $4,304,000 after buying an additional 9,638 shares in the last quarter.

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.